Research programme: antibody-based cancer therapeutics - Meditope Biosciences

Drug Profile

Research programme: antibody-based cancer therapeutics - Meditope Biosciences

Latest Information Update: 31 Aug 2016

Price : $50

At a glance

  • Originator Meditope Biosciences
  • Class Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 30 Aug 2016 Meditope Biosciences has eight patents issued worldwide related to Site-specific novel antibody platform technology .
  • 21 Apr 2015 Early research is ongoing in USA
  • 30 Jul 2013 Antibody-based cancer therapeutics programme is available for licensing (
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top